BESREMI
As listed in the register: BESREMI
500 mcg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ropeginterferon Alfa-2b
- Made by
- Forus Therapeutics Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (BESREMi). It describes the substance, not this exact product.
Interferon alfa belongs to the class of type I interferons, which exhibit their cellular effects in polycythemia vera and essential thrombocythemia in the bone marrow by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR).
Binding to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) and activator of transcription (STAT) proteins.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-25
Safety of the active substance
From the US prescribing label for the same active substance (BESREMi). It describes the substance, not this exact product.
WARNING: RISK OF SERIOUS DISORDERS Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
- BESREMi is contraindicated in patients with:.
- Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt..
- Hypersensitivity to interferons including interferon alfa-2b or any of the inactive ingredients of BESREMi..
- Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment..
The most common adverse reactions reported in >20% of patients were transaminase elevations, anemia, pyrexia, beta 2 microglobulin urine increased, bacterial infection, pruritus, and weight decreased.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Forus Therapeutics Inc. |
|---|---|
| Active substance | Ropeginterferon Alfa-2b |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 500 mcg |
| Form | solution |
| Classification | L03AB15 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02569728 |
| DPD drug code | 107193 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.